NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Sell
42
VRNA Quote, Financials, Valuation and Earnings
Last price:
$43.57
Seasonality move
:
-1.61%
Day range:
$40.10 - $42.86
52-week range:
$11.39 - $43.73
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
26.38x
Volume:
733.6K
Avg. volume:
1M
1-year change:
153.68%
Market cap:
$3.4B
Revenue:
--
EPS (TTM):
-$2.00
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
VRNA
Verona Pharma PLC
|
$2M | -$0.41 | -- | -2.08% | $47.29 |
|
ADAP
Adaptimmune Therapeutics PLC
|
$20.5M | -$0.18 | 4199.24% | -9.44% | $3.50 |
|
AUTL
Autolus Therapeutics PLC
|
$155K | -$0.22 | -61.82% | -46.14% | -- |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -- | -- | -- |
|
DBVT
DBV Technologies SA
|
$1.1M | -$1.77 | -- | -59.89% | -- |
|
TCBP
TC BioPharm (Holdings) PLC
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
VRNA
Verona Pharma PLC
|
$42.06 | $47.29 | $3.4B | -- | $0.00 | 0% | -- |
|
ADAP
Adaptimmune Therapeutics PLC
|
$0.60 | $3.50 | $154.8M | -- | $0.00 | 0% | 0.85x |
|
AUTL
Autolus Therapeutics PLC
|
$2.29 | -- | $609.4M | -- | $0.00 | 0% | -- |
|
BDRX
Biodexa Pharmaceuticals PLC
|
$3.90 | -- | $2.3M | -- | $0.00 | 0% | 3.52x |
|
DBVT
DBV Technologies SA
|
$3.19 | -- | $65.4M | -- | $0.00 | 0% | -- |
|
TCBP
TC BioPharm (Holdings) PLC
|
$0.67 | -- | $5.5M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
VRNA
Verona Pharma PLC
|
47.91% | -0.070 | 5.1% | 12.47x |
|
ADAP
Adaptimmune Therapeutics PLC
|
38.4% | 5.180 | 20.51% | 3.54x |
|
AUTL
Autolus Therapeutics PLC
|
-- | 4.339 | -- | 17.97x |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -0.555 | -- | -- |
|
DBVT
DBV Technologies SA
|
-- | -0.249 | -- | -- |
|
TCBP
TC BioPharm (Holdings) PLC
|
-- | -0.755 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
VRNA
Verona Pharma PLC
|
$5.1M | -$39.1M | -55.17% | -74.15% | -583.75% | -$62.7M |
|
ADAP
Adaptimmune Therapeutics PLC
|
-- | -$14.7M | -55.22% | -67.8% | -38.33% | -$54.9M |
|
AUTL
Autolus Therapeutics PLC
|
-- | -$67.7M | -80.74% | -80.74% | -331.28% | -$86.3M |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -- | -- | -- | -- |
|
DBVT
DBV Technologies SA
|
-- | -$30.3M | -- | -- | -- | -$22.9M |
|
TCBP
TC BioPharm (Holdings) PLC
|
-- | -$2.6M | -- | -- | -- | -$3.5M |
Verona Pharma PLC vs. Competitors
-
Which has Higher Returns VRNA or ADAP?
Adaptimmune Therapeutics PLC has a net margin of -763.91% compared to Verona Pharma PLC's net margin of -43.07%. Verona Pharma PLC's return on equity of -74.15% beat Adaptimmune Therapeutics PLC's return on equity of -67.8%.
Company Gross Margin Earnings Per Share Invested Capital VRNAVerona Pharma PLC90.35% -$0.56 $250.5M ADAPAdaptimmune Therapeutics PLC-- -$0.06 $129.9M -
What do Analysts Say About VRNA or ADAP?
Verona Pharma PLC has a consensus price target of $47.29, signalling upside risk potential of 12.42%. On the other hand Adaptimmune Therapeutics PLC has an analysts' consensus of $3.50 which suggests that it could grow by 274.78%. Given that Adaptimmune Therapeutics PLC has higher upside potential than Verona Pharma PLC, analysts believe Adaptimmune Therapeutics PLC is more attractive than Verona Pharma PLC.
Company Buy Ratings Hold Ratings Sell Ratings VRNAVerona Pharma PLC5 0 0 ADAPAdaptimmune Therapeutics PLC4 2 0 -
Is VRNA or ADAP More Risky?
Verona Pharma PLC has a beta of 0.464, which suggesting that the stock is 53.579% less volatile than S&P 500. In comparison Adaptimmune Therapeutics PLC has a beta of 2.179, suggesting its more volatile than the S&P 500 by 117.863%.
-
Which is a Better Dividend Stock VRNA or ADAP?
Verona Pharma PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adaptimmune Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verona Pharma PLC pays -- of its earnings as a dividend. Adaptimmune Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VRNA or ADAP?
Verona Pharma PLC quarterly revenues are $5.6M, which are smaller than Adaptimmune Therapeutics PLC quarterly revenues of $40.9M. Verona Pharma PLC's net income of -$43M is lower than Adaptimmune Therapeutics PLC's net income of -$17.6M. Notably, Verona Pharma PLC's price-to-earnings ratio is -- while Adaptimmune Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verona Pharma PLC is -- versus 0.85x for Adaptimmune Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VRNAVerona Pharma PLC-- -- $5.6M -$43M ADAPAdaptimmune Therapeutics PLC0.85x -- $40.9M -$17.6M
-
Which has Higher Returns VRNA or AUTL?
Autolus Therapeutics PLC has a net margin of -763.91% compared to Verona Pharma PLC's net margin of -522.15%. Verona Pharma PLC's return on equity of -74.15% beat Autolus Therapeutics PLC's return on equity of -80.74%.
Company Gross Margin Earnings Per Share Invested Capital VRNAVerona Pharma PLC90.35% -$0.56 $250.5M AUTLAutolus Therapeutics PLC-- -$0.31 $582M -
What do Analysts Say About VRNA or AUTL?
Verona Pharma PLC has a consensus price target of $47.29, signalling upside risk potential of 12.42%. On the other hand Autolus Therapeutics PLC has an analysts' consensus of -- which suggests that it could grow by 356.33%. Given that Autolus Therapeutics PLC has higher upside potential than Verona Pharma PLC, analysts believe Autolus Therapeutics PLC is more attractive than Verona Pharma PLC.
Company Buy Ratings Hold Ratings Sell Ratings VRNAVerona Pharma PLC5 0 0 AUTLAutolus Therapeutics PLC7 2 0 -
Is VRNA or AUTL More Risky?
Verona Pharma PLC has a beta of 0.464, which suggesting that the stock is 53.579% less volatile than S&P 500. In comparison Autolus Therapeutics PLC has a beta of 1.984, suggesting its more volatile than the S&P 500 by 98.37%.
-
Which is a Better Dividend Stock VRNA or AUTL?
Verona Pharma PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Autolus Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verona Pharma PLC pays -- of its earnings as a dividend. Autolus Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VRNA or AUTL?
Verona Pharma PLC quarterly revenues are $5.6M, which are smaller than Autolus Therapeutics PLC quarterly revenues of $10.1M. Verona Pharma PLC's net income of -$43M is higher than Autolus Therapeutics PLC's net income of -$82.1M. Notably, Verona Pharma PLC's price-to-earnings ratio is -- while Autolus Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verona Pharma PLC is -- versus -- for Autolus Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VRNAVerona Pharma PLC-- -- $5.6M -$43M AUTLAutolus Therapeutics PLC-- -- $10.1M -$82.1M
-
Which has Higher Returns VRNA or BDRX?
Biodexa Pharmaceuticals PLC has a net margin of -763.91% compared to Verona Pharma PLC's net margin of --. Verona Pharma PLC's return on equity of -74.15% beat Biodexa Pharmaceuticals PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital VRNAVerona Pharma PLC90.35% -$0.56 $250.5M BDRXBiodexa Pharmaceuticals PLC-- -- -- -
What do Analysts Say About VRNA or BDRX?
Verona Pharma PLC has a consensus price target of $47.29, signalling upside risk potential of 12.42%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of -- which suggests that it could grow by 105.52%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Verona Pharma PLC, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Verona Pharma PLC.
Company Buy Ratings Hold Ratings Sell Ratings VRNAVerona Pharma PLC5 0 0 BDRXBiodexa Pharmaceuticals PLC0 0 0 -
Is VRNA or BDRX More Risky?
Verona Pharma PLC has a beta of 0.464, which suggesting that the stock is 53.579% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.447, suggesting its more volatile than the S&P 500 by 44.69%.
-
Which is a Better Dividend Stock VRNA or BDRX?
Verona Pharma PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verona Pharma PLC pays -- of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VRNA or BDRX?
Verona Pharma PLC quarterly revenues are $5.6M, which are larger than Biodexa Pharmaceuticals PLC quarterly revenues of --. Verona Pharma PLC's net income of -$43M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, Verona Pharma PLC's price-to-earnings ratio is -- while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verona Pharma PLC is -- versus 3.52x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VRNAVerona Pharma PLC-- -- $5.6M -$43M BDRXBiodexa Pharmaceuticals PLC3.52x -- -- --
-
Which has Higher Returns VRNA or DBVT?
DBV Technologies SA has a net margin of -763.91% compared to Verona Pharma PLC's net margin of --. Verona Pharma PLC's return on equity of -74.15% beat DBV Technologies SA's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital VRNAVerona Pharma PLC90.35% -$0.56 $250.5M DBVTDBV Technologies SA-- -$1.60 -- -
What do Analysts Say About VRNA or DBVT?
Verona Pharma PLC has a consensus price target of $47.29, signalling upside risk potential of 12.42%. On the other hand DBV Technologies SA has an analysts' consensus of -- which suggests that it could grow by 590.04%. Given that DBV Technologies SA has higher upside potential than Verona Pharma PLC, analysts believe DBV Technologies SA is more attractive than Verona Pharma PLC.
Company Buy Ratings Hold Ratings Sell Ratings VRNAVerona Pharma PLC5 0 0 DBVTDBV Technologies SA0 0 0 -
Is VRNA or DBVT More Risky?
Verona Pharma PLC has a beta of 0.464, which suggesting that the stock is 53.579% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of 0.642, suggesting its less volatile than the S&P 500 by 35.828%.
-
Which is a Better Dividend Stock VRNA or DBVT?
Verona Pharma PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verona Pharma PLC pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VRNA or DBVT?
Verona Pharma PLC quarterly revenues are $5.6M, which are larger than DBV Technologies SA quarterly revenues of --. Verona Pharma PLC's net income of -$43M is lower than DBV Technologies SA's net income of -$30.4M. Notably, Verona Pharma PLC's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verona Pharma PLC is -- versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VRNAVerona Pharma PLC-- -- $5.6M -$43M DBVTDBV Technologies SA-- -- -- -$30.4M
-
Which has Higher Returns VRNA or TCBP?
TC BioPharm (Holdings) PLC has a net margin of -763.91% compared to Verona Pharma PLC's net margin of --. Verona Pharma PLC's return on equity of -74.15% beat TC BioPharm (Holdings) PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital VRNAVerona Pharma PLC90.35% -$0.56 $250.5M TCBPTC BioPharm (Holdings) PLC-- -$5.07 -- -
What do Analysts Say About VRNA or TCBP?
Verona Pharma PLC has a consensus price target of $47.29, signalling upside risk potential of 12.42%. On the other hand TC BioPharm (Holdings) PLC has an analysts' consensus of -- which suggests that it could grow by 349.17%. Given that TC BioPharm (Holdings) PLC has higher upside potential than Verona Pharma PLC, analysts believe TC BioPharm (Holdings) PLC is more attractive than Verona Pharma PLC.
Company Buy Ratings Hold Ratings Sell Ratings VRNAVerona Pharma PLC5 0 0 TCBPTC BioPharm (Holdings) PLC0 0 0 -
Is VRNA or TCBP More Risky?
Verona Pharma PLC has a beta of 0.464, which suggesting that the stock is 53.579% less volatile than S&P 500. In comparison TC BioPharm (Holdings) PLC has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock VRNA or TCBP?
Verona Pharma PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TC BioPharm (Holdings) PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verona Pharma PLC pays -- of its earnings as a dividend. TC BioPharm (Holdings) PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VRNA or TCBP?
Verona Pharma PLC quarterly revenues are $5.6M, which are larger than TC BioPharm (Holdings) PLC quarterly revenues of --. Verona Pharma PLC's net income of -$43M is lower than TC BioPharm (Holdings) PLC's net income of -$2.5M. Notably, Verona Pharma PLC's price-to-earnings ratio is -- while TC BioPharm (Holdings) PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verona Pharma PLC is -- versus -- for TC BioPharm (Holdings) PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VRNAVerona Pharma PLC-- -- $5.6M -$43M TCBPTC BioPharm (Holdings) PLC-- -- -- -$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 23
Quantum [QMCO] is down 3.03% over the past day.
Sell
46
NUKK alert for Dec 23
Nukkleus [NUKK] is up 3.83% over the past day.
Sell
1
IIPR alert for Dec 23
Innovative Industrial Properties [IIPR] is down 6.46% over the past day.
